The monoclonal antibody denosumab prevents fractures and increases survival in breast cancer patients receiving aromatase inhibitors. Credit: Nancy R. Gough, BioSerendipity

New Options for Limiting the Side Effects of Anti-Estrogen Breast Cancer Therapy

Clinical trial results show that the monoclonal antibody denosumab is effective in preventing fractures associated with anti-estrogen therapy and extends disease-free survival of breast cancer patients.

Nancy R. Gough, PhD

3 min readAug 7, 2019

--

Nancy R. Gough, PhD

Written by Nancy R. Gough, PhD

Scientist, editor, and writer with a PhD in Pharmacology

Help
Status
About
Careers
Blog
Privacy
Terms
Text to speech
Teams